Exhibit 126 · Randomized trial report
Remdesivir for the Treatment of Covid-19 — Final Report
The Kaplan-Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).
NIAID's trial randomized 1,062 hospitalized patients. Median recovery was 10 days on remdesivir and 15 on placebo (rate ratio 1.29, 95% CI 1.12–1.49). Day-29 mortality was 11.4% and 15.2% (hazard ratio 0.73, 95% CI 0.52–1.03), a difference that was not statistically significant. Serious adverse events were less frequent on remdesivir (24.6% vs 31.6%).
- Source
- John H. Beigel et al. (ACTT-1 Study Group), New England Journal of Medicine 383(19):1813–1826
- Date
- 5 November 2020
- Quoted from
- Abstract, Results (N Engl J Med 383:1813-26)
- Grade
- Peer-reviewed
- Document
- https://doi.org/10.1056/NEJMoa2007764
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit